Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and Deoxyribonuclease (human clone protein moiety); Dornasa alfa. Date of last search for all years available: 20 May Using the option ‘ Advanced search’, the following search terms were entered into the following fields. El impacto de primer año de tratamiento con dornasa alfa en los parámetros clínicos de pacientes con fibrosis quística: resultado de estudio brasileño.

Author: Shakazilkree Meztizil
Country: Switzerland
Language: English (Spanish)
Genre: Literature
Published (Last): 19 May 2005
Pages: 320
PDF File Size: 18.23 Mb
ePub File Size: 5.9 Mb
ISBN: 458-7-21739-534-6
Downloads: 53379
Price: Free* [*Free Regsitration Required]
Uploader: Taramar

Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity. Do not use a double dose to make up for a missed one. It usually is taken one or two times a day.

Keep all appointments with your doctor and the laboratory. Similarly, our findings show a stabilization of lung function parameters at 6 and 12 months of dornase alfa, with no dornasw in FEV 1 over the one year period as it would be expected S aureusP.

Acute maxillary sinusitis caused by M.

National Center for Biotechnology InformationU. Views Read Edit View history.

Regarding variations in clinical management of the various centers, regular updating and contact between researchers have minimized differences in basic care approaches and monitoring of patients.


Pulmonary complications of cystic fibrosis. Dornase alfa is a biosynthetic form of human DNase I. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information. dornzsa

Only use a nebulizer that is recommended by your doctor. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location — one that is up and away and out of their sight and reach. For each patient, these three forms and the following parameters were collected: It was also recommended for CF patients with mild lung disease by the European Consensus The responsible physician evaluated patient’s medical record forms covering the last six months, prior to study entry T0and alfw 6 months T2 and 12 months T4 of dornase alfa.


Support Center Support Center. In the last six months of therapy, chronic or intermittent colonization by P. To review the literature evaluating the efficacy of dornase alfa for non-cystic fibrosis pediatric patients with pulmonary atelectasis.

Ddornasa dornase alfa exactly as directed. Due to sample size limitations, no statistical comparisons were made for this group regarding outcomes over time.

Dornase alfa – DrugBank

Improvements in CF diagnosis and treatment strategies led to an increase in life expectancy, raising the median age of survival to 36 years in the United States 1 and around 18 years in Brazil 9.


Mutations found dotnasa our study dornsa among the most common mutations detected in CF 1 In summary, we have observed that CF patients have significant disease morbidity despite all routine therapies that they receive in CF centers. Journal List Rev Paul Pediatr v. Copyright and License information Disclaimer.

Dornase Alfa pronounced as door’ nace. It breaks down the thick secretions in the airways, allowing air to flow eornasa and preventing bacteria from building up.

Dornase Alfa for Non-Cystic Fibrosis Pediatric Pulmonary Atelectasis.

Dornase alfa is an orphan drug. Prospective evaluation of emerging bacteria in cystic fibrosis. Drugs acting on the respiratory system Recombinant proteins.

DNase recombinant human deoxyribonuclease. In view of the current recommendations regarding dornaea use of dornase alfa, it was decided not to have a control group, as the use of placebo or another mucolytic drug would be ethically questionable 5 When chronic and intermittent colonization were grouped, P.